Skip to content

Isobaric levobupivacaine with or without clonidine for spinal anaesthesia

Evaluation of analgesic efficacy of clonidine as an additive to isobaric levobupivacaine in patients undergoing lower limb surgeries: A randomised controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030367
Enrollment
40
Registered
2021-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Subarachnoid block: SUbarachnoid block will be given and block characteristics will be compared Control Intervention1: Subarachnoid block: 15 mg of 0.5% isobaric levobupivacaine (3ml) +

Sponsors

Guru Teg Bahadur Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I or II between 18-65 years height 150-180 cm

Exclusion criteria

Exclusion criteria: � Patients who do not give consent for subarachnoid block. Patients with contraindication to subarachnoid block: infection at injection site, coagulopathy, space-occupying lesion, increased intracranial tension, known case of seizure disorder, pre-existing neurological deficit, and spine deformity. History of allergy to any drug being used in the study. Pregnant patients. Known case of hepatic and renal disease, drug addicts and chronic alcoholics. Patients who are on antiarrhythmic drugs.

Design outcomes

Primary

MeasureTime frame
Duration of effective analgesiaTimepoint: ONce Time from the subarachnoid block to the time of patient�s first complaint of pain and VAS more than 3

Secondary

MeasureTime frame
Sensory and motor block charactersiticsTimepoint: every 2 min for the first 10 min and then every 5 min till the same level is obtained in 3 consecutive readings

Countries

India

Contacts

Public ContactDr Harsh Rathore

University College of Medical Sciences, Delhi

rsramb@gmail.com9625900699

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026